

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

On

TOWNSEND and TOWNSEND and CREW LLP

By:

Dana Kane

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT
Attorney Docket No.: 20695C-003100US
Client Ref. No.: WM-206.00

RECEIVED

APR 25 2002

TECH CENTER 1600/2900

#17
MB
05/01/02

In re application of:

REDL *et al.*

Application No.: 09/486,516

Filed: February 28, 2000

For: FIBRINOGEN-BASED TISSUE
ADHESIVE CONTAINING AN
ELASTASE INHIBITOR

Examiner: Michael V. Meller

Art Unit: 1651

RESPONSE TO SUPPLEMENTAL
RESTRICTION REQUIREMENT

COPY OF PAPER
ORIGINALLY FILED

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Supplemental Restriction Requirement mailed February 13, 2002, applicants submit the following. A petition for a one-month extension of time with appropriate fee accompanies this response, now due April 13, 2002.

Applicants elect the following species:

For claims 33-35, Applicants elect human proteins;

For claim 45, Applicants elect aprotinin; and

For claim 47, Applicants elect betalactams.

Applicants also elect specie #1, the tissue adhesive with fibrinogen, elastase inhibitor and plasminogen.

Respectfully submitted,

Annette S. Parent

Reg. No. 42,058

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200; Fax: (415) 576-0300

SF 1334585 v1